Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA × anti-CD3 diabodies from lentivirally transduced human lymphocytes

Cancer Gene Therapy

Volumn 14, Issue 4, 2007, Pages 380-388

  Compte, M ^a   Blanco, B ^a   Serrano, F ^b   Cuesta, A M ^a   Sanz, L ^a   Bernad, A ^c   Holliger, P ^d   Alvarez Vallina L ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Recombinant antibodies; T lymphocytes; Tumor immunity

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD3 ANTIBODY; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL LINE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; GROWTH RATE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CARCINOEMBRYONIC ANTIGEN; CELL PROLIFERATION; GENE THERAPY; GENETIC VECTORS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33947264398     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701021     Document Type: Article

References (24)

1. Ockert D, Schmitz M, Hampl M, Rieber EP. Advances in cancer immunotherapy. Immunol Today 1999; 20: 63-65.
2. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-494.
3. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996; 26: 2304-2309.
4. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11: 558-562.
5. Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol 2004; 25: 85-91.
6. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-1136.
7. Blanco B, Holliger P, Vile RG, Alvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171: 1070-1077.
8. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 1999; 59: 2909-2916.
9. Coleman HM, Brierley I, Stevenson PG. An internal ribosome entry site directs translation of the murine gammaherpesvirus 68 MK3 open reading frame. J Virol 2003; 77: 13093-13105.
10. Haas DL, Case SS, Crooks GM, Kohn DB. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol Ther 2000; 2: 71-80.
11. Afanasieva TA, Wittmer M, Vitaliti A, Ajmo M, Neri D, Klemenz R. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther 2003; 10: 1850-1859.
12. Sanz L, Kristensen P, Blanco B, Facteau S, Russell SJ, Winter G et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Therapy 2002; 9: 1049-1053.
13. Ailles LE, Naldini L. HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol 2002; 261: 31-52.
14. Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med 2004; 6: 963-973.
15. Schlegel R, Tralka TS, Willingham MC, Pastan I. Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 1983; 32: 639-646.
16. + cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996; 70: 2581-2585.
17. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
18. Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci USA 1996; 93: 15266-15271.
19. Hefta LJ, Chen FS, Ronk M, Sauter SL, Sarin V, Oikawa S et al. Expression of carcinoembryonic antigen and its predicted immunoglobulin-like domains in HeLa cells for epitope analysis. Cancer Res 1992; 52: 5647-5655.
20. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996; 24: 406-415.
21. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
22. Larcher F, Del Rio M, Serrano F, Segovia JC, Ramirez A, Meana A et al. A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. FASEB J 2001; 15: 1529-1538.
23. Sanchez-Arevalo LV, Cuesta AM, Sanz L, Compte M, Garcia P, Prieto J et al. Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer 2006; 119: 455-462.
24. Blanco B, Holliger P, Alvarez-Vallina L. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Cancer Gene Therapy 2002; 9: 275-281.